Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene Symbol | FBXW7 | ||||||||||
Synonyms | AGO | CDC4 | DEDHIL | FBW6 | FBW7 | FBX30 | FBXO30 | FBXW6 | hAgo | hCdc4 | SEL-10 | SEL10 | ||||||||||
Gene Description | FBXW7, F-box/WD repeat-containing protein 7, is part of the SCF E3 ubiquitin-protein ligase complex, which plays a role in the degradation of proteins involved in cell division and cell growth (PMID: 17909001, PMID: 22673505). FBXW7 mutations have been associated with cholangiocarcinoma and acute lymphocytic leukemia (PMID: 17909001) and have been identified in many other cancers, including colorectal (PMID: 28424412), endometrial, and stomach cancer (PMID: 17909001). | ||||||||||
|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT05687136 | Phase I | M1774 + Peposertib | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors | Recruiting | USA | 0 |
NCT02873975 | Phase II | Prexasertib | A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | Completed | USA | 0 |
NCT05867251 | Phase Ib/II | ARTS-021 + Fulvestrant + Ribociclib ARTS-021 + Letrozole + Ribociclib ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin Abemaciclib + ARTS-021 + Fulvestrant Abemaciclib + ARTS-021 + Letrozole ARTS-021 + Fulvestrant ARTS-021 | Study of AVZO-021 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03718091 | Phase II | Berzosertib | M6620 (VX-970) in Selected Solid Tumors | Completed | USA | 0 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |